剖腹產傷口懷孕~~為何不能~~生下來？

剖腹產傷口懷孕為何不能生下來？csp

Methotrexate therapy for cesarean section scar pregnancy with and without suction curettage

Jian-Hua Wang, M.D., Kai-Hong Xu, M.D., Jun Lin, M.D., Jian-Yun Xu, M.D., Rui-Jin Wu, Ph.D, M.D.
Received 17 June 2008; received in revised form 26 July 2008; accepted 29 July 2008. published online 30 October 2008.

Objective

To compare the clinical effects in women with cesarean scar pregnancy (CSP) who were treated with either methotrexate (MTX) regimen only or MTX regimen followed by dilation and curettage (D&C).

Design

Prospective consecutive clinical cohort study.

Setting

University hospital for obstetrics, gynecology, and reproductive medicine.

Subject(s)

Seventy-one cases of CSP.

Intervention(s)

The subjects were treated with either MTX only (MTX group, 21 cases) or MTX followed by D&C (combined therapy group, 50 cases).

Main Outcome Measure(s)

Success rates, hysterectomy rates, and time to resolution of serum β-hCG and the CSP mass were compared between the two groups.

Result(s)

Compared with the MTX group, the combined therapy group had a shorter time to resolution of the CSP mass and serum β-hCG. There was no significant difference between the MTX and combined therapy groups regarding success rates (76.2% vs. 90.0%, respectively) and hysterectomy rates (19.0% vs. 8.0%, respectively).

Conclusion(s)

Both therapies could treat the majority of CSP patients successfully, but the combined therapy resulted in a shorter time of therapy and indicated a more favorable effect.

Category:

People & Blogs

Tags:

• 剖腹產傷口懷孕為何不能生下來？